Urinary Tract Infection News, Treatment Studies | UTI Research Articles

Urinary Tract Infections (UTI)

URINARY TRACT INFECTIONS (UTI)

cre-carbapenem-resistant-enter

Novel Antibiotic Combo Beats Piperacillin-Tazobactam in Complicated UTI Trial

The combination of cefepime, a cephalosporin antibiotic, and enmetazobactam, a novel extended-spectrum β-lactamase inhibitor (Exblifep; Allecra Therapeutics) was found to be superior to piperacillin-tazobactam in the treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis, according to top-line results from the phase 3 ALLIUM trial. The double-blind, non-inferiority study included 1034 patients randomized to…

Fetroja Now Available for Treatment of Complicated UTI

Fetroja® (cefiderocol) has been made available by Shionogi for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.

Fetroja Approved for Complicated UTI in Patients With Limited or No Alternative Tx Options

The Food and Drug Administration (FDA) has approved Fetroja (cefiderocol; Shionogi) for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex. The treatment is indicated for patients aged ≥18 years with limited or no alternative…
Next post in Urinary Tract Infections (UTI)